During the General Assembly, the HARMONY Alliance Partners and Associated Members discussed challenges, lessons learned in both in the 8 Work Packages and in the 7 HM diseases; multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-hodgkin’s lymphoma (NHL), myelodysplastic syndromes (MDS), and pediatric hematologic malignancies (HMs). The two-day program provided many opportunities for networking and targeted meetings on specific issues, varying from data governance and analysis modelling to ethical considerations in relation to Big Data.
More information about the results of the General Assembly soon to come.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
